Ruifu Chemical Supply Intermediates of Saxagliptin
Saxagliptin CAS 361442-04-8
Saxagliptin Hydrate CAS 945667-22-1
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4
Saxagliptin-N-Boc Amide CAS 361440-67-7
(R)-1-Boc-3-Aminopiperidine CAS 188111-79-7
| Chemical Name |
Saxagliptin |
| Synonyms |
BMS-477118; Onglyza; (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-Hydroxy-1-Adamantyl)acetyl]-2-Azabicyclo[3.1.0]hexane-3-Carbonitrile; (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-Hydroxytricyclo [3.3.1.13,7]dec-1-yl)acetyl]-2-Azabicyclo[3.1.0]hexane-3-Carbonitrile |
| CAS Number |
361442-04-8 |
| CAT Number |
RF-PI1991 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C18H25N3O2 |
| Molecular Weight |
315.41 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White Powder |
| Odor |
Characteristic |
| identification |
A: IR B: HPLC Retention Time |
| Purity / Analysis Method |
>99.0% (HPLC) |
| Clarity of Water Solution |
Transparent, Colorless, None Suspended Matters |
| Sieve Analysis |
100% Pass 80 Mesh |
| Melting Point |
202.0~212.0℃ |
| Loss on Drying |
<0.50% |
| Sulphated Ash |
<0.20% |
| Specific Rotation |
+174.0°~+186.0° |
| Single Impurity |
<0.50% |
| Total Impurities |
<1.00% |
| Heavy Metals |
<10ppm |
| Arsenic (As) |
<2ppm |
| Lead (Pb) |
<1ppm |
| Cadmium (Cd) |
<1ppm |
| Residual Solvents |
<100ppm |
| Residual Pesticide |
Negative |
| Microbiology |
|
| Total Plate Count |
<1000cfu/g |
| Yeast & Mold |
<100cfu/g |
| E. Coli |
Negative |
| S. Aureus |
Negative |
| Salmonella |
Negative |
| Shelf Life |
24 Months |
| Test Standard |
Enterprise Standard |
| Usage |
API; Type 2 Diabetes Mellitus |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Saxagliptin (BMS-477118) (CAS: 361442-04-8) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research. Saxagliptin is a type 2 diabetes drug that can stimulate the pancreas to produce more insulin after the meal. It was reached by the cooperation of AstraZeneca and Bristol-Myers Squibb Company and belongs to DPP-IV inhibitor. Saxagliptin plays the role through inhibiting GLP-l degradation. GLP-I is the hormones naturally produced in the intestine after taking food. It can regulate the secretion of insulin and strengthen the utilization of glucose in the peripheral tissues. The single medication of Saxagliptin can improve blood glucose control and the combined medication of Saxagliptin with Metformin, Sulfonylurea and Thiazolidinediones can enhance curative effect. It leads to low risk of hypoglycemia and its adverse reactions are similar to placebo, showing better tolerance. On July 31, 2009, Saxagliptin tablets (Onglyza), a new drug of type 2 diabetes, jointly researched and developed AstraZeneca and Bristol-Myers Squibb was approved by the US FDA. It can be taken once a day to treat type 2 diabetes combined with controlling Diet and exercise.